Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc has demonstrated strong growth in its Telehealth segment, with a year-over-year increase of 14% in active subscribers, reaching 310,818 by the end of the third quarter of 2025. The company reported total revenue of $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue increasing by 17.4% to $47.3 million. Additionally, the gross margin expanded to 87%, indicating a favorable revenue mix which bodes well for the company’s overall profitability and potential for further growth.

Bears say

LifeMD Inc. faces significant challenges that contribute to a negative outlook for its stock, including lower than projected telehealth revenue growth and difficulties in patient acquisition and retention. The company reported third-quarter revenue of $60.2 million, a 13% year-over-year increase, but it fell short of consensus expectations and guidance, while adjusted EBITDA also did not meet forecasts. Additionally, revenue guidance for full-year 2025 has been reduced, now anticipated to be between $192 million and $193 million, highlighting concerns about the sustainability of its revenue growth amidst increased competition and operational adjustments.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.